Martínez, Esteban <br/><br/>
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravir.  [electronic resource] 

 -  AIDS (London, England)  Nov 2012 
 - 2315-26 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1473-5571 
<br/><br/><label>Standard No.: </label>10.1097/QAD.0b013e328359f29c  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Anti-HIV Agents--pharmacology<br/>Atherosclerosis--blood<br/>Biomarkers--blood<br/>C-Reactive Protein--metabolism<br/>Chemokine CCL2--blood<br/>Drug Administration Schedule<br/>E-Selectin--metabolism<br/>Fasting<br/>Female<br/>Follow-Up Studies<br/>HIV Infections--drug therapy<br/>HIV Protease Inhibitors--pharmacology<br/>Humans<br/>Interleukin-10--blood<br/>Interleukin-6--blood<br/>Lipids--blood<br/>Male<br/>Middle Aged<br/>Osteoprotegerin--blood<br/>P-Selectin--metabolism<br/>Pyrrolidinones--pharmacology<br/>Raltegravir Potassium<br/>Ritonavir--pharmacology<br/>Tumor Necrosis Factor-alpha--blood<br/>Vascular Cell Adhesion Molecule-1--blood